Lacking Overall IMspiration for Triplet Therapy in Melanoma? A Review of the Interim Analysis of IMspire150
Author:
Publisher
Society of Cutaneous Oncology
Reference26 articles.
1. Ascierto, Paolo A, Daniil Stroyakovskiy, Helen Gogas, Caroline Robert, Karl Lewis, Svetlana Protsenko, Rodrigo P Pereira, et al. 2023. "Overall Survival with First-Line Atezolizumab in Combination with Vemurafenib and Cobimetinib in BRAFV600 Mutation-Positive Advanced Melanoma (IMspire150): Second Interim Analysis of a Multicentre, Randomised, Phase 3 Study." The Lancet Oncology 24 (1): 33-44. https://doi.org/10.1016/s1470-2045(22)00687-8.
2. Atkins, Michael B., Sandra J. Lee, Bartosz Chmielowski, Ahmad A. Tarhini, Gary I. Cohen, Thach-Giao Truong, Helen H. Moon, et al. 2023. "Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq TrialECOG-ACRIN EA6134." Journal of Clinical Oncology 41 (2): 186-97. https://doi.org/10.1200/jco.22.01763.
3. Boni, Andrea, Alexandria P. Cogdill, Ping Dang, Durga Udayakumar, Ching-Ni Jenny Njauw, Callum M. Sloss, Cristina R. Ferrone, et al. 2010. "Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma Without Affecting Lymphocyte Function." Cancer Research 70 (13): 5213-19. https://doi.org/10.1158/0008-5472.can-10-0118.
4. Cooper, Zachary A, Dennie T Frederick, Vikram R Juneja, Ryan J Sullivan, Donald P Lawrence, Adriano Piris, Arlene H Sharpe, David E Fisher, Keith T Flaherty, and Jennifer A Wargo. 2013. "BRAF Inhibition Is Associated with Increased Clonality in Tumor-Infiltrating Lymphocytes." OncoImmunology 2 (10): e26615. https://doi.org/10.4161/onci.26615.
5. Dummer, Reinhard, Georgina V. Long, Caroline Robert, Hussein A. Tawbi, Keith T. Flaherty, Paolo A. Ascierto, Paul D. Nathan, et al. 2022. "Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib forBRAFV600Mutant Unresectable or Metastatic Melanoma." Journal of Clinical Oncology 40 (13): 1428-38. https://doi.org/10.1200/jco.21.01601.
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Immunotherapy and Cardiovascular Health - A Cause for Concern?;Journal of Cutaneous Oncology;2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3